Acute Coronary Syndrome Market

 Market Overview:

The 7 major acute coronary syndrome markets reached a value of US$ 6.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 9.2 Billion by 2034, exhibiting a growth rate (CAGR) of 3.49% during 2024-2034.

The acute coronary syndrome market has been comprehensively analyzed in IMARC's new report titled "Acute Coronary Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034".  Acute coronary syndrome refers to a group of clinical conditions that occur due to a sudden decrease or complete blockage of blood flow to the heart. As a result, the cardiac muscle fails to receive enough oxygen, thereby impairing its ability to pump blood effectively. This syndrome mainly consists of ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina. The symptoms of acute coronary syndrome can vary from person to person, and some patients may experience atypical or no symptoms at all. Various other common indications associated with the ailment include chest pain or discomfort, which may radiate to the left arm, shoulder, jaw or back, shortness of breath, nausea, vomiting, lightheadedness, cold sweats, indigestion, racing heartbeat, etc. Acute coronary syndrome can be diagnosed through a comprehensive physical examination, clinical feature assessment, and medical history evaluation. Blood tests are also performed to measure certain enzymes and biomarkers, like troponin T and creatine kinase-MB, which are released into the bloodstream if the heart muscle is damaged. Furthermore, the healthcare provider may conduct several diagnostic procedures, such as coronary angiography, radionuclide myocardial perfusion imaging, electrocardiogram, etc., to confirm a diagnosis.

The increasing cases of atherosclerosis, in which the fatty deposits (plaque) accumulate within the arteries and restrict blood flow to the heart, are primarily driving the acute coronary syndrome market. In addition to this, the rising incidences of various associated risk factors, including stress, substance abuse, advancing age, high blood pressure, obesity, smoking, etc., are also bolstering the market growth. Moreover, the inflating adoption of effective medications, like antiplatelets, anticoagulants, pain relievers, etc., to improve blood flow and decrease chest pain in patients is acting as another significant growth-inducing factor. Apart from this, the escalating demand for coronary artery bypass grafting techniques, since they help to restore oxygen and nutrient supply to the affected areas and boost long-term survival rates, is further creating a positive outlook for the market. Additionally, the emerging popularity of drug-eluting stents, which inhibit the excessive growth of smooth muscle cells, thereby significantly reducing the risk of restenosis as compared to conventional therapies, is expected to drive the acute coronary syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the acute coronary syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute coronary syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute coronary syndrome market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the acute coronary syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the acute coronary syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current acute coronary syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the acute coronary syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the acute coronary syndrome market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the acute coronary syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of acute coronary syndrome across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of acute coronary syndrome by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of acute coronary syndrome by gender across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of acute coronary syndrome by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with acute coronary syndrome across the seven major markets?
• What is the size of the acute coronary syndrome patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of acute coronary syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Acute Coronary Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for acute coronary syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute coronary syndrome market?
• What are the key regulatory events related to the acute coronary syndrome market?
• What is the structure of clinical trial landscape by status related to the acute coronary syndrome market?
• What is the structure of clinical trial landscape by phase related to the acute coronary syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the acute coronary syndrome market?